All Blue Capital in $773 million bid for Zymeworks

(Corrects April 28 story to remove reference to debt in paragraph 3. The error was repeated in previous versions of the story.) By Anirban Sen (Reuters) -Investment firm All Blue Capital has approached Zymeworks Inc, a developer of antibody therapies f…